Great people,
Many achieve satisfactory results at semaglutide 1.0 or 1.7 mg, or at tirzepatide 10 mg, and stay there indefinitely
However, it is important to note that retatrutide has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains an experimental treatment
Weight Loss: In phase III trials, weight loss with the use of exenatide averaged between 0.9 and 2.8 kg over a 30-month time frame, with more weight loss associated when exenatide is added to existing metformin therapy
Consistency in medication use, combined with a healthy lifestyle, plays a crucial role in achieving and maintaining weight loss
Coaching can support adherence and habits, but it does not alter the pharmacology